GRAPHENO, LLC — Department of Defense SBIR Phase II: SBIR PHASE II AWARD FOR PROPOSAL TITLED HALOVAX: CLAY NANOTUBE-BASED VACCINE DELIVERY PATC

GRAPHENO, LLC — SBIR Phase II award from Department of Defense.

Phase II SBIR prototype / development signal

  • Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
  • Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
  • Obligated amount $1,299,832 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
  • Tagged technology areas: Materials & Manufacturing, Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.

Informational capture context from public federal data — not legal or bid advice.

Summary

Grapheno, LLC received over $1.2 million from the Department of Defense to develop HALOVAX, a patch using clay nanotubes to deliver HIV vaccine slowly over time. This technology aims to improve vaccine effectiveness through sustained release.

Amount
$1,299,832
Agency
Department of Defense · Defense Health Agency
Program / Phase
SBIR · Phase II
NAICS
541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
Place of performance
LA
Period
2026-04-08 → 2028-08-07

Technology domains

Materials & Manufacturing Human Performance & Medical

Description

SBIR PHASE II AWARD FOR PROPOSAL TITLED HALOVAX: CLAY NANOTUBE-BASED VACCINE DELIVERY PATCHES FOR THE SUSTAINED RELEASE OF AN HIV VACCINE

View on USASpending.gov ↗